Adiponectin, an adipokine with anti-inflammatory, antioxidant, and anti-fibrotic properties, is markedly reduced during the progression from NAFLD to NASH (83). Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.